Myriad Genetics, Inc. (MYGN) has a MoatMap StockRank of 20/100 based on Quality (39/100), Value (49/100), and Momentum (23/100) factor scores. The current signal is SELL. Myriad Genetics, Inc., a US healthcare company focused on genetic testing, does not have a clear, compelling connection to any of the identified macro themes. The 'STRONG_SELL' signal suggests underlying fundamental issues or valuation concerns that are not offset by a powerful macro tailwind.